Eton Pharmaceutical’s Alkindi Sprinkle (hydrocortisone) Receives US FDA’s Approval as Replacement Therapy in Pediatric Patients
Eton Pharmaceutical’s Alkindi Sprinkle (hydrocortisone) Receives US FDA’s Approval as Replacement Therapy in Pediatric Patients
Shots:
- The approval is based on 6 clinical studies, including the 1st and only interventional P-lll study which involves the assessing of Alkindi Sprinkle (hydrocortisone) for Pediatric AI in neonates to children under 8 yrs. of age
- Eton expects Alkindi Sprinkle to be commercially available in the Q4’ 2020 and it will be available in four strengths: 0.5mg, 1mg, 2mg, and 5mg, to give greater dosing flexibility to clinicians
- Alkindi Sprinkle is the 1st and only FDA-approved granular hydrocortisone formulation for the treatment of adrenocortical insufficiency specifically designed for use in children
Click here to read the full press release/ article | Ref: Globenewswire | Image: Eton Pharma